DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.

This clinical trial is looking at a combination of drugs called vemurafenib and cobimetinib. Vemurafenib is approved as standard of care for adult patients with unresectable or metastatic melanoma. Cobimetinib is approved as standard of care in combination with vemurafenib for the treatment of adult patients with unresectable or metastatic melanoma.
Cobimetinib and vemurafenib work in patients with these types of cancers which have certain changes in the cancer cells called BRAF V600 mutation-positive.
Investigators now wish to find out if it will be useful in treating patients with other cancer types which are also BRAF V600 mutation-positive. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.
This trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.

本临床试验针对威罗菲尼（vemurafenib）与考比替尼（cobimetinib）的联合用药方案开展研究。威罗菲尼单药已获批作为不可切除或转移性黑色素瘤成人患者的标准治疗方案；考比替尼联合威罗菲尼的方案，亦已获批用于此类成人患者的标准治疗。
威罗菲尼与考比替尼仅对癌细胞携带BRAF V600突变阳性（BRAF V600 mutation-positive）特征的此类癌症患者具有治疗效果。本研究团队当前旨在探究该联合方案对其他同样携带BRAF V600突变阳性的癌症类型患者是否具备治疗价值。若试验结果呈阳性，研究团队将与英国国民保健署（National Health Service, NHS）及癌症药物基金（Cancer Drugs Fund）合作，探索未来能否让患者常规获取并使用上述药物。
本临床试验是名为DETERMINE的试验项目的组成部分。该项目还将以相同模式开展其他抗肿瘤药物的研究，即通过将药物与罕见癌症类型或携带特定突变的癌症类型进行精准匹配，实现用药适配。